188 related articles for article (PubMed ID: 2858383)
1. Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates.
Rettenmeier AW; Prickett KS; Gordon WP; Bjorge SM; Chang SL; Levy RH; Baillie TA
Drug Metab Dispos; 1985; 13(1):81-96. PubMed ID: 2858383
[TBL] [Abstract][Full Text] [Related]
2. Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid.
Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Baillie TA
Drug Metab Dispos; 1986; 14(4):454-64. PubMed ID: 2873993
[TBL] [Abstract][Full Text] [Related]
3. Metabolic fate of valproic acid in the rhesus monkey. Formation of a toxic metabolite, 2-n-propyl-4-pentenoic acid.
Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Lockard JS; Thummel KE; Baillie TA
Drug Metab Dispos; 1986; 14(4):443-53. PubMed ID: 2873992
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P-450-mediated dehydrogenation of 2-n-propyl-2(E)-pentenoic acid, a pharmacologically-active metabolite of valproic acid, in rat liver microsomal preparations.
Kassahun K; Baillie TA
Drug Metab Dispos; 1993; 21(2):242-8. PubMed ID: 8097692
[TBL] [Abstract][Full Text] [Related]
5. The covalent binding to protein of valproic acid and its hepatotoxic metabolite, 2-n-propyl-4-pentenoic acid, in rats and in isolated rat hepatocytes.
Porubek DJ; Grillo MP; Baillie TA
Drug Metab Dispos; 1989; 17(2):123-30. PubMed ID: 2565201
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans.
Kassahun K; Farrell K; Abbott F
Drug Metab Dispos; 1991; 19(2):525-35. PubMed ID: 1676665
[TBL] [Abstract][Full Text] [Related]
7. In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analog 4-pentenoic acid.
Kassahun K; Abbott F
Drug Metab Dispos; 1993; 21(6):1098-106. PubMed ID: 7905390
[TBL] [Abstract][Full Text] [Related]
8. Enantiotopic differentiation during the biotransformation of valproic acid to the hepatotoxic olefin 2-n-propyl-4-pentenoic acid.
Porubek DJ; Barnes H; Meier GP; Theodore LJ; Baillie TA
Chem Res Toxicol; 1989; 2(1):35-40. PubMed ID: 2519229
[TBL] [Abstract][Full Text] [Related]
9. Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes.
Kassahun K; Hu P; Grillo MP; Davis MR; Jin L; Baillie TA
Chem Biol Interact; 1994 Mar; 90(3):253-75. PubMed ID: 8168173
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid.
Rettie AE; Rettenmeier AW; Howald WN; Baillie TA
Science; 1987 Feb; 235(4791):890-3. PubMed ID: 3101178
[TBL] [Abstract][Full Text] [Related]
11. Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status.
Tang W; Borel AG; Fujimiya T; Abbott FS
Chem Res Toxicol; 1995; 8(5):671-82. PubMed ID: 7548749
[TBL] [Abstract][Full Text] [Related]
12. Comparative transfer of valproic acid and of an active metabolite into brain and liver: possible pharmacological and toxicological consequences.
Löscher W; Nau H
Arch Int Pharmacodyn Ther; 1984 Aug; 270(2):192-202. PubMed ID: 6435554
[TBL] [Abstract][Full Text] [Related]
13. Studies on the beta-oxidation of valproic acid in rat liver mitochondrial preparations.
Bjorge SM; Baillie TA
Drug Metab Dispos; 1991; 19(4):823-9. PubMed ID: 1680661
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of unsaturated derivatives of valproic acid in rat liver microsomes and destruction of cytochrome P-450.
Prickett KS; Baillie TA
Drug Metab Dispos; 1986; 14(2):221-9. PubMed ID: 2870898
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid and active unsaturated metabolite (2-en): transfer to mouse liver following human therapeutic doses.
Nau H; Loscher W
Biopharm Drug Dispos; 1985; 6(1):1-8. PubMed ID: 3921077
[TBL] [Abstract][Full Text] [Related]
16. Characterization of thiol-conjugated metabolites of 2-propylpent-4-enoic acid (4-ene VPA), a toxic metabolite of valproic acid, by electrospray tandem mass spectrometry.
Tang W; Abbott FS
J Mass Spectrom; 1996 Aug; 31(8):926-36. PubMed ID: 8799319
[TBL] [Abstract][Full Text] [Related]
17. A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics.
Tang W; Abbott FS
Drug Metab Dispos; 1997 Feb; 25(2):219-27. PubMed ID: 9029053
[TBL] [Abstract][Full Text] [Related]
18. Pyruvate uptake is inhibited by valproic acid and metabolites in mitochondrial membranes.
Aires CC; Soveral G; Luís PB; ten Brink HJ; de Almeida IT; Duran M; Wanders RJ; Silva MF
FEBS Lett; 2008 Oct; 582(23-24):3359-66. PubMed ID: 18775709
[TBL] [Abstract][Full Text] [Related]
19. Conjugation of glutathione with a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, catalyzed by rat hepatic glutathione-S-transferases.
Tang W; Borel AG; Abbott FS
Drug Metab Dispos; 1996 Apr; 24(4):436-46. PubMed ID: 8801059
[TBL] [Abstract][Full Text] [Related]
20. Bioactivation of a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, via glucuronidation. LC/MS/MS characterization of the GSH-glucuronide diconjugates.
Tang W; Abbott FS
Chem Res Toxicol; 1996 Mar; 9(2):517-26. PubMed ID: 8839057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
